Patents by Inventor Kan He
Kan He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240133975Abstract: A computerized simulation validating method for a full-scale distribution network single phase-to-ground fault test is implemented by simulating a full-scale test system with external quantities being controlled to be conformant and validating the full-scale distribution network single phase-to-ground fault test based on a conformance check result between the internal quantities of the field testing and the internal quantities of the simulation testing. The simulation validating method for a full-scale distribution network single phase-to-ground fault test improves normalization and conformance of the full-scale distribution network ground fault test. The computerized simulation validating system, apparatus, and medium for a full-scale distribution network single phase-to-ground fault test also achieve the benefits noted above.Type: ApplicationFiled: August 10, 2023Publication date: April 25, 2024Inventors: Zhi LI, Shaofeng YU, Dingfang KE, Peibo WANG, Kan SUN, Weiqiang LANG, Haijiang XU, Kelong WANG, Zhiyong LI, Kun YU, Guangyao YING, Xuqiang HE, Yezhao CHEN, Xiang ZHANG, Mingxiao DU, Huijuan GUI, Hongling HU, Biao PENG, Xubin XIAO
-
Patent number: 11690891Abstract: Provided herein is a method for improving the health of an intestinal epithelial barrier using Aloe vera. The method may include administering Aloe vera extracts to intestinal epithelial cells. The decolorized aloe extract may be whole leaf extract, whole leaf dry extract, inner leaf dry extract, digested whole leaf extract, digested whole leaf dry extract, digested inner leaf dry extract, or a combination thereof.Type: GrantFiled: November 4, 2019Date of Patent: July 4, 2023Assignee: Herbalife International of America, Inc.Inventors: Michael T. Yatcilla, Troy Smillie, Joosang Park, Isabel Andrea Garcia Tornadu, Andrea Bertocco, Kan He
-
Patent number: 11547719Abstract: Acetylated polysaccharides and methods of making and using them are provided. One method of making acetylated polysaccharides includes providing polysaccharides, purifying the polysaccharides to 1-90% purity by weight, providing an acetylation agent, providing a catalyst, mixing the acetylation agent and catalyst with the polysaccharides, thereby manufacturing acetylated polysaccharides, and purifying the acetylated polysaccharides.Type: GrantFiled: September 28, 2020Date of Patent: January 10, 2023Assignee: Herbalife International of America, Inc.Inventors: Joosang Park, Zhichao Bao, Qunyi Zheng, Kan He, Troy Smillie, Zhaoyang Xie
-
Patent number: 11236080Abstract: The present invention is directed to novel protein kinase inhibitors comprising the chemical compound N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-(3-hydroxypyrrolidin-1-yl)pyrimidin-4-yl]amino]thiazole-5-carboxamide, its pharmaceutically acceptable salts, enantiomers, and enantiomeric mixtures, and methods of use to treat protein kinase-mediated diseases or conditions.Type: GrantFiled: December 19, 2019Date of Patent: February 1, 2022Assignee: Princeton Drug Discovery, IncInventor: Kan He
-
Publication number: 20210008098Abstract: Acetylated polysaccharides and methods of making and using them are provided. One method of making acetylated polysaccharides includes providing polysaccharides, purifying the polysaccharides to 1-90% purity by weight, providing an acetylation agent, providing a catalyst, mixing the acetylation agent and catalyst with the polysaccharides, thereby manufacturing acetylated polysaccharides, and purifying the acetylated polysaccharides.Type: ApplicationFiled: September 28, 2020Publication date: January 14, 2021Inventors: Joosang Park, Zhichao Bao, Qunyi Zheng, Kan He, Troy Smillie, Zhaoyang Xie
-
Patent number: 10844355Abstract: A method is provided to measure modulation of phosphatidylcholine export transport and/or formation activity in hepatocyte or stable cell-line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, and RNA. Furthermore, the method is designed to determine modulation of phosphatidylcholine transport and/or formation activity not only by said test agents, but also their metabolites or biotransformed products formed in situ.Type: GrantFiled: March 4, 2019Date of Patent: November 24, 2020Assignee: Princeton Bioinnovation LLCInventor: Kan He
-
Publication number: 20200123148Abstract: The present invention is directed to novel protein kinase inhibitors comprising the chemical compound N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-(3-hydroxypyrrolidin-1-yl)pyrimidin-4-yl]amino]thiazole-5-carboxamide, its pharmaceutically acceptable salts, enantiomers, and enantiomeric mixtures, and methods of use to treat protein kinase-mediated diseases or conditions.Type: ApplicationFiled: December 19, 2019Publication date: April 23, 2020Applicant: Princeton Drug Discovery IncInventor: Kan He
-
Patent number: 10556897Abstract: The present invention is directed to novel protein kinase inhibitors comprising the chemical compound N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-(3-hydroxypyrrolidin-1-yl)pyrimidin-4-yl]amino]thiazole-5-carboxamide, its pharmaceutically acceptable salts, enantiomers, and enantiomeric mixtures, and methods of use to treat protein kinase-mediated diseases or conditions.Type: GrantFiled: November 2, 2018Date of Patent: February 11, 2020Assignee: Princeton Drug Discovery, IncInventor: Kan He
-
Publication number: 20200041491Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.Type: ApplicationFiled: October 8, 2019Publication date: February 6, 2020Applicant: Biotranex LLCInventor: Kan He
-
Patent number: 10479786Abstract: The present invention concerns novel deuterated and non-deuterated cyclic chemical compounds and their corresponding salts thereof active on protein kinases in general, and in particular as inhibitors of protein kinases. Additionally, methods of treating mammals with protein kinase-mediated diseases or conditions by administering a therapeutically effective amount of the novel deuterated or non-deuterated cyclic chemical compound and their corresponding salts thereof.Type: GrantFiled: December 12, 2017Date of Patent: November 19, 2019Assignee: Princeton Drug Discovery, IncInventor: Kan He
-
Patent number: 10481149Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.Type: GrantFiled: August 11, 2017Date of Patent: November 19, 2019Assignee: Biotranex, LLCInventor: Kan He
-
Publication number: 20190203172Abstract: A method is provided to measure modulation of phosphatidylcholine export transport and/or formation activity in hepatocyte or stable cell-line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, and RNA. Furthermore, the method is designed to determine modulation of phosphatidylcholine transport and/or formation activity not only by said test agents, but also their metabolites or biotransformed products formed in situ.Type: ApplicationFiled: March 4, 2019Publication date: July 4, 2019Applicant: Biotranex, LLCInventor: Kan He
-
Patent number: 10280401Abstract: A method is provided to measure modulation of phosphatidylcholine export transport and/or formation activity in hepatocyte or stable cell-line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, amino acids, peptides, proteins, oligonucleotides, DNA, and RNA. Furthermore, the method is designed to determine modulation of phosphatidylcholine transport and/or formation activity not only by said test agents, but also their metabolites or biotransformation products formed in situ.Type: GrantFiled: March 29, 2016Date of Patent: May 7, 2019Assignee: Biotranex, LLCInventor: Kan He
-
Publication number: 20190071437Abstract: The present invention is directed to novel protein kinase inhibitors comprising the chemical compound N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-(3-hydroxypyrrolidin-1-yl)pyrimidin-4-yl]amino]thiazole-5-carboxamide, its pharmaceutically acceptable salts, enantiomers, and enantiomeric mixtures, and methods of use to treat protein kinase-mediated diseases or conditions.Type: ApplicationFiled: November 2, 2018Publication date: March 7, 2019Applicant: Princeton Drug Discovery IncInventor: Kan He
-
Patent number: 10174018Abstract: The present invention is directed to novel protein kinase inhibitors comprising the chemical compound N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-(3-hydroxypyrrolidin-1-yl)pyrimidin-4-yl]amino]thiazole-5-carboxamide, its pharmaceutically acceptable salts, enantiomers, and enantiomeric mixtures, and methods of use to treat protein kinase-mediated diseases or conditions.Type: GrantFiled: December 12, 2017Date of Patent: January 8, 2019Assignee: Princeton Drug Discovery IncInventor: Kan He
-
Patent number: 10106538Abstract: Protein kinases are regulators of cellular signaling and their functional dysregulation is common in carcinogenesis and many other disease states or disorders. The present invention relates to novel chemical entities that have biological activity to modulate mammalian protein kinase enzymes. In particular, compounds of the invention display potent inhibition of breast tumor related kinase (BRK).Type: GrantFiled: December 29, 2017Date of Patent: October 23, 2018Assignee: Princeton Drug Discovery IncInventors: Kan He, Lining Cai
-
Publication number: 20180118745Abstract: Protein kinases are regulators of cellular signaling and their functional dysregulation is common in carcinogenesis and many other disease states or disorders. The present invention relates to novel chemical entities that have biological activity to modulate mammalian protein kinase enzymes. In particular, compounds of the invention display potent inhibition of breast tumor related kinase (BRK).Type: ApplicationFiled: December 29, 2017Publication date: May 3, 2018Applicant: PRINCETON DRUG DISCOVERY INCInventors: Kan He, Lining Cai
-
Patent number: 9956241Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: GrantFiled: February 27, 2015Date of Patent: May 1, 2018Assignee: Naturex, S.A.Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
-
Publication number: 20180099960Abstract: The present invention concerns novel deuterated and non-deuterated cyclic chemical compounds and their corresponding salts thereof active on protein kinases in general, and in particular as inhibitors of protein kinases. Additionally, methods of treating mammals with protein kinase-mediated diseases or conditions by administering a therapeutically effective amount of the novel deuterated or non-deuterated cyclic chemical compound and their corresponding salts thereof.Type: ApplicationFiled: December 12, 2017Publication date: April 12, 2018Applicant: Princeton Drug Discovery IncInventor: Kan He
-
Publication number: 20180099959Abstract: The present invention concerns novel deuterated and non-deuterated cyclic chemical compounds and their corresponding salts thereof active on protein kinases in general, and in particular as inhibitors of protein kinases. Additionally, methods of treating mammals with protein kinase-mediated diseases or conditions by administering a therapeutically effective amount of the novel deuterated or non-deuterated cyclic chemical compound and their corresponding salts thereof.Type: ApplicationFiled: December 12, 2017Publication date: April 12, 2018Applicant: Princeton Drug Discovery IncInventor: Kan He